On November 4, 2025, AmacaThera announced that it signed an exclusive global licensing agreement with Pacira Biosciences for up to US$230 million, validating its tunable drug delivery platform.
AmacaThera is a leading developer of next-generation hydrogel-based drug delivery solutions. Using a proprietary blend of known polymers, AmacaThera’s clinically validated hydrogel platform is transforming drug delivery by enabling the precise, tunable and sustained release of a wide range of therapeutics, from small molecules to biologics.
Osler, Hoskin & Harcourt LLP acted as legal advisors to AmacaThera on this transaction with a team led by Christine Jackson (Commercial) and including Alex Gorka (Corporate), Gary Marshall (Emerging and High Growth Companies), Alan Kenisberg (Tax) and Ryan Howes (Intellectual Property).
Key Contact
Partner, Commercial, Toronto
Team
Partner, Corporate, Toronto
Partner, Emerging and High Growth Companies, Toronto
Partner, Tax, Toronto
Associate, Intellectual Property, Ottawa
